Soft-tissue sarcomas are a group of malignant tumours whose clinical management is complicated by morphological heterogeneity, inadequate molecular markers and limited therapeutic options. Receptor tyrosine kinases (RTKs) have been shown to play important roles in cancer, both as therapeutic targets and as prognostic biomarkers. An initial screen of gene expression data for 48 RTKs in 148 sarcomas showed that ROR2 was expressed in a subset of leiomyosarcoma (LMS), gastrointestinal stromal tumour (GIST) and desmoid-type fibromatosis (DTF). This was further confirmed by immunohistochemistry (IHC) on 573 tissue samples from 59 sarcoma tumour types. Here we provide evidence that ROR2 expression plays a role in the invasive abilities of LMS and GIST cells in vitro. We also show that knockdown of ROR2 significantly reduces tumour mass in vivo using a xenotransplantation model of LMS. Lastly, we show that ROR2 expression, as measured by IHC, predicts poor clinical outcome in patients with LMS and GIST, although it was not independent of other clinico-pathological features in a multivariate analysis, and that ROR2 expression is maintained between primary tumours and their metastases. Together, these results show that ROR2 is a useful prognostic indicator in the clinical management of these soft-tissue sarcomas and may represent a novel therapeutic target.
Introduction
Sarcomas, a group of tumours originating from mesenchymal cells, account for approximately 1% of malignancies. Most sarcomas demonstrate locally aggressive growth and distant haematogenous spread [1] . Leiomyosarcomas (LMSs) are malignant tumours of smooth muscle that show a high degree of molecular heterogeneity and are characterized by local recurrence and metastasis; currently there exist no targeted therapies for LMS. Gastrointestinal stromal tumours (GISTs) arise from the interstitial cells of Cajal in the gastrointestinal tract wall and have been shown to respond to treatment with the tyrosine kinase inhibitor imatinib. However, almost all GIST patients eventually B Edris et al and mutations in ROR2 can cause diseases such as brachydactyly type B and Robinow syndrome [4, 5] .
Recently, ROR2 has been shown to have protumourigenic effects in osteosarcoma, melanoma and renal cell carcinoma (RCC) cell lines [6] [7] [8] . However, the expression of ROR2, as well as its functional and prognostic significance, has yet to be evaluated in soft-tissue sarcomas. Here, we describe the levels of ROR2 mRNA in 148 soft-tissue sarcomas and we examine the expression of ROR2 protein in 573 additional soft-tissue sarcoma samples, representing 59 diagnostic subtypes. We also provide evidence that in vitro invasive abilities of LMS and GIST cells are affected by ROR2 expression and that suppression of ROR2 significantly reduces in vivo tumour mass in a xenotransplantation model of LMS. We further show that high ROR2 expression in LMS and GIST tumours is significantly associated with poor clinical outcome, and that ROR2 expression is consistent between primary tumours and their metastases. Together, these results show that ROR2 is a novel prognostic biomarker and potential therapeutic target in LMS and GIST.
Materials and methods

Case material
For gene expression profiling, frozen tissue from 148 soft-tissue tumours was used (see Supporting information, Table S1 ). For confirmation of ROR2 expression by IHC, we used a tissue microarray (TMA) with 573 cases from 59 sarcoma types (Table 1) . For IHC studies on specimens with known clinical outcome data, we studied an additional 410 GISTs, 147 LMSs and 90 DTFs, which had been obtained at primary diagnosis and which were distributed over 10 TMAs [9] [10] [11] [12] (see Supporting information, Table S3 ). Only four GIST cases had received imatinib therapy during the period of follow-up.
Human exonic evidence-based oligonucleotide (HEEBO) gene arrays
The HEEBO microarray platform used contained 44 544 70-mer probes that were designed using a transcriptome-based annotation of exonic structure for genomic loci. After confirmation of histology and viable tumours by frozen section, specimens were homogenized in Trizol (Invitrogen, Carslbad, CA, USA). Total RNA was extracted and reversetranscribed into cDNA, using a mixture of oligo dT (Operon, Huntsville, AL, USA) and random hexamers (Amersham Biosciences, Little Chalfont, UK) with incorporation of amino allyl-dUTP (Ambion, Austin, TX, USA). Cy3 and Cy5 dyes (Amersham) were used for indirect cDNA labelling from universal human reference RNA (Stratagene, La Jolla, CA, USA) and tumour specimen cDNA, respectively. Microarray hybridization and washing was done using standard procedures [7, 8] . Microarrays were scanned on a GenePix 4000 microarray scanner and fluorescence ratios (tumour/reference) were calculated using GenePix software. Only spots with a ratio of signal over a background of at least 1.3 in the Cy5 and 1.5 in the Cy3 channel were included. Gene centring was applied to the expression values. Only genes with >50% available data were analysed. Data are available through the Stanford Microarray Database (http://smd.stanford.edu).
Cell culture
LMS04, LMS05, GIST48 and GIST882 cells were derived from primary clinical specimens (LMS04, retroperitoneal lesion that spread from primary uterine LMS; LMS05, primary thigh LMS; GIST48, primary GIST with homozygous exon 11 KIT mutation (V560D), and heterozygous exon 17 KIT mutation (D820A); GIST882, primary GIST with homozygous exon 13 KIT mutation (K642E) [16] ). LMS04 and LMS05 cells were maintained in RPMI 1640 (Invitrogen) supplemented with 10% fetal bovine serum (FBS; Invitrogen). GIST48 and GIST882 cells were maintained in IMDM (Invitrogen) supplemented with 15% FBS. All cell lines were supplemented with 100 U/ml penicillin/streptomycin and 4 mM L-glutamine (Invitrogen) and were maintained at 37
• C in 5% CO 2 .
Small interfering RNA transfections LMS04, LMS05 and GIST48 cells were seeded at 80 000 cells/well (in six-well plates) and 5000 cells/well (in 96-well plates) in antibiotic-free medium. After overnight adherence, cells were transfected with a pool of control siRNAs (siNT, siGENOME NonTargeting siRNA Pool #1, Dharmacon, Lafayette, CO, USA) or a pool of ROR2-specific siRNAs (siROR2, ROR2 siGENOME SMARTpool, Dharmacon) at a 20 nM concentration in OptiMEM (Invitrogen) using Lipofectamine 2000 (Invitrogen). siRNA knockdown efficiencies were measured using quantitative real-time PCR. Cell proliferation was quantified with tetrazolium salt (WST-1) colorimetric assay (Roche Molecular Biochemicals, Mannheim, Germany).
ROR2 plasmid transfections
2 000 000 GIST882 cells were suspended with 5 μg plasmid DNA in 100 μl of Nucleofector Solution V and electroporated using an Amaxa Nucleofector II machine (program T-030) with full-length human ROR2 or empty control plasmids (OriGene, Rockville, MD, USA). A TurboGFP plasmid (OriGene) was used as a transfection control. 
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Matrigel invasion assays
Invasion assays were performed using polyethylene terephthalate invasion chambers with 8.0 μm pores (BD Bioscience, Bedford, MA, USA). Cells were transfected with siROR2 or siNT for 48 h, serumstarved for 16 h, counted and seeded (20,000 cells) onto the filters. 20% FBS medium was placed in the lower well as a chemoattractant. 400 ng/ml recombinant human Wnt5A (R&D Systems, Minneapolis, MN, USA) was added for 16 h prior to invasion. The cells were allowed to invade for 24 h before being fixed in 10% formalin, stained with crystal violet (SigmaAldrich, St. Louis, MO, USA), washed with water and counted. All experiments were performed in triplicate.
Western blotting and immunoprecipitation
Protein lysates were prepared from cell monolayers using RIPA buffer (Thermo Scientific) supplemented with protease and phosphatase inhibitors (Roche) and PMSF (Sigma-Aldrich). Protein concentrations were determined with the Bio-Rad Protein Assay (Bio-Rad Laboratories). Immunoprecipitations were performed with an anti-human ROR2 antibody [13] coupled to Protein G Dynabeads (Invitrogen) from 300 μg total protein, and 30 μg whole cell lysate were used as input controls. Denaturing SDS buffer (Invitrogen) was added and samples were heated to 95
• C for 5 min. Electrophoresis and immunoblotting were performed using NuPAGE BisTris gels and nitrocellulose membranes (Invitrogen). Protein expression and phosphorylation changes were visualized by chemiluminescence and were captured using a GelDoc system (Bio-Rad) and processed using GIMP and Inkscape software. β-Actin was detected using a mouse monoclonal antibody (Sigma-Aldrich), phosphotyrosine was detected using a mouse monoclonal antibody (Cell Signaling Technology) and ROR2 was detected using the monoclonal antibody described previously [13] .
Stable cell line generation
LMS05 cells were infected with MISSION Lentviral Transduction Particles (Sigma-Aldrich) expressing a non-targeting scramble control shRNA (clone SHC002V) or one of two ROR2-specific shRNAs (ROR2 shRNA #1, clone TRCN0000001492; ROR2 shRNA #2, clone TRCN0000001493). Stable cells were selected using 2 μg/ml puromycin (SigmaAldrich).
Xenotransplantation experiments
LMS05 cells stably expressing scrambled or one of two ROR2-specific shRNAs were suspended in RPMI containing 25% Matrigel (BD Biosciences) and 100 000 cells were implanted subcutaneously on the backs of 6 week-old NOD/SCID/interleukin (IL)-2Rγ null (NSG) mice. The animals were euthanized after 8 weeks and the tumours were resected, weighed and fixed in formalin for histological analysis and IHC. Tumour weights were compared using t-tests. All procedures followed protocols approved by the Stanford Committee on Animal Research.
ROR2 immunohistochemistry
Slides were cut to a thickness of 4 μm, deparaffinized in xylene and hydrated in a graded series of alcohols. The deparaffinized slides were then boiled by microwave for 12 min in citrate buffer, pH 6. A primary mouse anti-human ROR2 monoclonal antibody was used at a 1 : 25 dilution [13] . The IHC reactions were visualized using the EnVision+ system (Dako, Carpinteria, CA, USA) with diaminobenzidine. The cores were scored as follows: 2, strong staining, whether diffusely or focally present in the tumour; 1, weak staining, whether diffusely or focally present in the tumour; 0, absence of any staining (Figure 1) . A score of 2 was considered positive for subsequent statistical analyses.
Statistical analyses
Kaplan-Meier analysis in GraphPad Prism v 5.0 (GraphPad Software, San Diego, CA, USA) was used to generate survival curves with log-rank tests to compare patient outcome between groups. Multivariate Cox proportional models were generated to assess clinicopathological features and their association with patient outcome using the coxph function in the Survival R package. p < 0.05 was considered significant.
Results
ROR2 mRNA and protein expression in soft-tissue tumours
To determine the differences in expression of RTKs in soft-tissue sarcomas, we analysed the transcript levels of 48 different RTKs, using gene microarray expression data from 148 soft-tissue tumours (see Supporting information, Tables S1, S2). We identified ROR2 as a gene that had low or undetectable levels in the majority of sarcoma subtypes analysed but that showed high levels of expression in a subset of LMS, GIST, desmoid-type fibromatosis (DTF) and dermatofibrosarcoma protuberans (DFSP) cases (Figure 1) .
To confirm ROR2 expression in these tumours and to expand on these findings, we next performed an IHC study using TMAs that contained 573 softtissue sarcomas and benign soft-tissue tumours, which did not overlap with the 148 cases used for gene expression profiling. Similar to our gene array findings, most tumour types on the TMAs failed to react with the ROR2 antibody but a significant subset of LMS, GIST, DTF and DFSP cases showed strong IHC reactivity (Table 1) . Representative stains scored as strongly positive, weakly positive or negative are shown in Figure 2 for LMS and GIST and in Figure S5 (see Supporting information) for DTF. Many tumour ROR2 in soft-tissue sarcomas samples showed staining of the cytoplasmic membrane, consistent with the predicted localization of ROR2; in some, the membrane staining was obscured by strong staining of the cytoplasm.
ROR2 expression mediates the invasive abilities of LMS and GIST cells in vitro
For functional studies, we used two human LMS and two human GIST cell lines. ROR2 mRNA and protein were highly expressed in LMS05 and GIST48, as demonstrated by strong membrane staining for ROR2 protein and high levels of ROR2 transcript; ROR2 expression was undetectable in LMS04 ( Figure 3A ; see also Supporting information, Figure S1 ). To explore whether ROR2 may mediate an aggressive tumour phenotype in soft-tissue sarcomas, we performed in vitro cell proliferation and matrigel invasion experiments, using pooled siRNAs targeting ROR2 (siROR2) or non-targeting control siRNAs (siNT). Upon siROR2 treatment, a strong reduction in ROR2 mRNA was observed ( Figure 3B ). siRNA treatment did not have an impact on the doubling time or viability of these cell lines (see Supporting information, Figure S2A-C) . However, in ROR2-positive LMS05 and GIST48 cells, siROR2 treatment led to an approximate 50% reduction in the invasive ability of these cells as compared to siNT treatment; no differences in the invasion rate of ROR2-negative LMS04 were observed ( Figure 3C ). Treatment with ROR2-ligand Wnt5A resulted in an increase in endogenous ROR2 receptor activation as measured by tyrosine phosphorylation (Figure 3D -E) and led to a significant increase in invasion of the ROR2-positive LMS05 and GIST48 cells, an effect which was abrogated by siROR2 treatment. In contrast, ROR2-negative LMS04 showed no significant response to Wnt5A treatment ( Figure 3F ).
To further investigate whether ROR2 mediates an aggressive sarcoma tumour cell phenotype, we used a fourth sarcoma cell line, GIST882, which expresses B Edris et al Figure 3 . Effects of in vitro ROR2 down-regulation and activation on invasive LMS and GIST cell lines. ROR2 protein expression was analysed by IHC on paraffin-embedded pellets of cell lines (scale bar = 35 μm) in LMS04, LMS05 and GIST48 (A). siROR2 treatment down-regulated ROR2 transcript levels and inhibited the invasion of ROR2-positive LMS05 and GIST48 cells through matrigel chambers, whereas no effect is seen in ROR2-negative LMS04 (B, C). GIST48 cells were treated with ROR2-ligand Wnt5A and cell lysates were precipitated with anti-ROR2 antibody and subjected to immunoblotting with anti-phosphotyrosine (top) or anti-ROR2 (bottom) antibodies (D). Wnt5A-treated GIST48 whole-cell lysates were subjected to immunoblotting with anti-phosphotyrosine (top), anti-ROR2 (middle) or anti-actin (bottom) antibodies (E). Treatment of ROR2-positive LMS05 and GIST48 with Wnt5A increased cell invasion, an effect that was diminished by siROR2 treatment; ROR2-negative LMS04 showed no response to treatment with Wnt5A (F). All experiments were performed in triplicate; error bars are ±1 SD; * * p < 0.01, * p < 0.05, as determined by Student's t-test. very low levels of ROR2 ( Figure 4A ; see also Supporting information, Figure S1 ). In contrast to LMS04, LMS05 and GIST48, GIST882 had a low baseline rate of in vitro matrigel invasion, making it an ideal candidate to explore the role of ROR2 over-expression in minimally invasive sarcoma cells. Upon transfection with a full-length human ROR2 cDNA, ROR2 mRNA and protein levels were strongly up-regulated ( Figure 4B, C) . This ROR2 up-regulation had no effect on cell growth kinetics (see Supporting information, Figure S2D ) but resulted in a greater than two-fold increase in the in vitro invasion rate of these cells ( Figure 4D ). Together, these results demonstrate that ROR2 expression can mediate the invasiveness of softtissue sarcoma cells in vitro. Two ROR2-specific shRNA constructs (shROR2-1 and shROR2-2) and a scrambled shRNA control were stably introduced into ROR2-positive LMS05 cells, and ROR2 knockdown was confirmed ( Figure 5A ). Similar to what we observed with transient ROR2 transfections, stable down-regulation of ROR2 resulted in no alterations in cell viability or doubling time in vitro (see Supporting information, Figure S3 ). The three cell lines were then engrafted subcutaneously in NSG mice and were allowed to grow for 8 weeks before the mice were euthanized. We found that mice engrafted with shROR2-1 and shROR2-2 LMS05 cells showed 2.6-fold and a 2.9-fold reduction in average tumour mass, respectively, which represented statistically significant decreases as compared to the mice whose LMS05 xenograft tumours expressed the scrambled control shRNA (shROR2-1, p = 0.0308; shROR2-2, p = 0.0197; Figure 5B ). Histological examination of the resected xenotransplanted tumours showed that all three LMS05-derivative cell lines maintained similar spindle-cell morphologies and IHC showed that the down-regulation of ROR2 had been maintained in shROR2-1 and shROR2-2 tumours ( Figure 5C ).
ROR2 in soft-tissue sarcomas
Prognostic significance of ROR2 expression in LMS, GIST and DTF
To determine whether ROR2 expression is correlated with patient survival in soft-tissue sarcomas, we performed IHC for ROR2 expression on TMAs comprised of 147 LMS, 410 GIST and 90 DTF cases with clinical follow-up data (see Supporting information, Table  S3 ). The clinico-pathological features of these cases have been published previously [11] [12] [13] [14] and are briefly described below. The LMS cases consisted of 74 gynaecological LMS (Gyn-LMS) and 73 non-gynaecological LMS (Non-gyn-LMS); the clinical outcome data available was disease-specific survival (DSS) and the median follow-up time was 3.1 years. None of the LMS patients had received neoadjuvant treatment in the form of chemotherapy and/or radiotherapy. For the 410 GIST cases, overall survival data were available for each patient and the follow-up period was up to 20 years from the time of diagnosis. Only four of the GIST patients analysed had received imatinib treatment during the follow-up period. For the 90 DTF cases, clinical outcome data consisted of time to disease recurrence and the median follow-up period for patients that did not have a recurrence was 5.85 years. For each tumour type, clinical data were used to generate Kaplan-Meier curves and to calculate logrank (Mantel-Cox) tests to determine whether survival was significantly affected in patients whose tumours expressed ROR2. In addition, a hazard ratio (HR) and its associated 95% confidence interval (CI) were calculated to quantify the effect of ROR2 expression on patient outcomes. For all analyses, cases staining strongly for ROR2 expression (IHC score 2) were compared to those that stained weakly or not at all (IHC scores 1 and 0; Figure 1 ; see also Supporting information, Figure S4 ).
In DTF, we found no significant association between ROR2 expression and disease recurrence (HR = 0.9797; CI, 0.5268-1.822; p = 0.9482; see Supporting information, Figure S5 ). In GIST, tumours with high ROR2 expression were associated with decreased overall survival rates when compared to cases that expressed ROR2 weakly or not at all (HR = 1.417; CI, 1.060-1.893; p = 0.0186; Figure 6A ). LMS patients whose tumour samples were strongly positive for Figure 6B , C). We next assessed whether ROR2 expression was independent of other clinico-pathological variables in predicting patient survival. For GIST, we constructed multivariate Cox proportional hazards models that considered ROR2 expression, tumour size, mitotic rate and anatomical location. For gynaecological and non-gynaecological LMS, similar multivariate analyses were conducted using ROR2 expression, Ki67 status, Fédération Nationale des Centres de Lutte Contre le Cancer (FNLCC) grade, and necrosis as inputs. Despite its prognostic utility as a stand-alone IHC marker, we found that high ROR2 expression was not associated with survival in GIST or LMS, independent of the other clinico-pathological features considered (Table 2 ).
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ROR2 expression is a stable property of LMS tumours
We next examined the consistency of ROR2 expression between 37 primary gynaecological and nongynaecological LMS samples and their corresponding metastatic lesions. We found that in primary tumours that were scored as ROR2-positive by IHC (score 2, Figure 2) , seven of nine (77.8%) maintained high ROR2 expression in at least one of their distant metastases. In primary tumours with low or absent ROR2 expression (score 1 or 0, Figure 2) , 20 of 28 (71.4%) maintained this lack of ROR2 expression in their associated metastases, whereas eight of 28 (28.6%) of tumours showed a gain of strong ROR2 expression in at least one of their metastatic growths ( Figure 7 ).
Discussion
Experimental and clinical studies have shown that deregulated RTKs can play important roles in cancer development and progression, and RTKs have proved to be amenable therapeutic targets in a wide range of cancer types. One of these RTKs, ROR2, is known to regulate cell migration during vertebrate development by acting as a receptor or co-receptor for Wnt5A. Recently, experiments have shown that Wnt5A-ROR2 signalling is important for the invasive abilities of melanoma, osteosarcoma and RCC cell lines, thereby making ROR2 a candidate biomarker of tumours with aggressive growth potential or a novel therapeutic target [18] .
Here we present the first large-scale characterization of ROR2 expression in human soft-tissue sarcomas. Our gene expression results from 148 sarcomas were confirmed and expanded by performing IHC on 573 cases representing 59 tumours. In addition to LMS, GIST, DTF and DFSP, small numbers of ROR2-positive cases were found in high-grade undifferentiated sarcoma. A significant proportion of cases displayed strong levels of ROR2 expression at the cell membrane. Consistent with the IHC scoring used for HER2 in breast cancer, only those cases with strong membrane reactivity were scored as positive.
Similar to results shown for melanoma, osteosarcoma and RCC cell lines, inhibition of ROR2 expression strongly decreased the in vitro invasiveness of two highly invasive ROR2-positive LMS and GIST cell lines. A third invasive cell line (LMS04), derived from an ROR2-negative LMS, also showed significant invasive capacity in vitro and exhibited no difference in invasion under the same experimental conditions, indicating that while ROR2 is functionally important for the subset of tumours in which it is expressed, it is not the only factor that determines tumour cell invasiveness. Treatment of ROR2-positive GIST48 cells with ROR2-specific ligand Wnt5A increased the activation of endogenous ROR2, as measured by immunoblotting for phosphotyrosine in cell lysates precipitated with an anti-ROR2 antibody. Previous studies highlighting the interaction between ROR2 and Wnt5A in human tumour cell lines relied on experiments utilizing exogenously expressed ROR2 cDNA constructs; in contrast, our data show that Wnt5A indeed activates endogenous ROR2. Concomitant with this increase in ROR2 receptor activation was a significant increase in cell invasion ROR2 in soft-tissue sarcomas Figure 6 . ROR2 expression predicts poor clinical outcome in patients with GIST and LMS. Kaplan-Meier survival curves for GIST and LMS cases stratified by ROR2 protein expression. High ROR2 expression predicted poor overall survival in patients with GIST (A) and poor disease-specific survival in patients with both gynaecological LMS (B) and non-gynaecological LMS (C).
of GIST48 and LMS05; upon ROR2 down-regulation, this increased invasion was strongly abrogated, suggesting that in ROR2-positive LMS and GIST cells, the aggressive tumour phenotype induced by Wnt5A is likely mediated through ROR2. A fourth cell line (GIST882), derived from an ROR2-negative, minimally invasive GIST tumour, demonstrated a marked increase in in vitro invasiveness upon transfection with a plasmid encoding human ROR2 as compared to a control plasmid, further demonstrating a potential role for ROR2 in mediating an aggressive tumour phenotype.
In addition, two independent ROR2 knockdown LMS cell lines derived from LMS05 showed diminished in vivo growth capacity as compared to a control cell line in a xenotransplantation model of LMS. While decreasing ROR2 expression did not diminish cell proliferation in vitro, the smaller tumour sizes observed in ROR2-down-regulated xenotransplanted tumours may result from an impairment of these cells to successfully invade into surrounding tissues, thereby decreasing the exposure of cell-surface growth factors to proliferative signals being secreted by normal cells in the tumour microenvironment.
SUPPORTING INFORMATION ON THE INTERNET
The following supporting information may be found in the online version of this article: Figure S1 . Baseline ROR2 mRNA expression in sarcoma cell lines. Table S1 . List of sarcoma cases used for gene microarray analysis. 
